drugset

drugset / Trial / NCT03764228

Human Amniotic Epithelial Cells Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation

NCT03764228 ↗

Unknown 27 enrolled Peking University People's Hospital Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China · collab

NaSingle-groupOpen-labelPrevention

Summary

This is a Single arm clinical study evaluating the safety and efficacy of hAECs in preventing aGVHD after HSCT.

Timeline

Start: 2020-07-01
Primary completion: 2021-07-01
Completion: 2022-07-01

Publications

Yang PJ, Zhao XY, Kou YH, Liu J, Ren XY, Zhang YY, Wang ZD, Ge Z, Yuan WX, Qiu C, Tan B, Liu Q, Shi YN, Jiang YQ, Qiu C, Guo LH, Li JY, Huang XJ, Yu LY. Human amniotic epithelial stem cell is a cell therapy candidate for preventing acute graft-versus-host disease. Acta Pharmacol Sin. 2024 Nov;45(11):2339-2353. doi: 10.1038/s41401-024-01283-y. Epub 2024 May 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	hAECs	Cell therapy	1e+06 cells/kg	—
Subject	hAECs	Cell therapy	2e+06 cells/kg	—
Subject	hAECs	Cell therapy	5e+06 cells/kg	—

Indications